Market Overview
The global ticagrelor
market size is predicted to grow USD 2.94 billion by 2030 a striking CAGR 6.40%
during the forecast period 2023-2030 owing to the rising patient population
suffering from heart problems, asserts Market Research Future (MRFR). Ticagrelor
is referred to as an antiplatelet drug, a member of the pharmaceuticals sectionwhich
helps to tackle the problem of platelet aggression. It keeps the platelets from
coagulating in order to prevent unwanted blood clots that can occur with
certain blood vessel or heartconditions. Ticagrelor outperformed an established
product named Clopidogrel by the SOC in the clinical trials in terms of safety
of the patients and end results. The drug is also used as an agent to reduce
stent thrombosis. Ticagrelor is a product of an already established entity, AstraZeneca,
and will be offered enough market space to achieve high growth rates in the
market.
Competitive Dashboard
The global ticagrelor
market players are
·
Alexion,
·
Ingelheim,
·
Roche,
·
Ingelheim Pfizer,
·
Pfizer,
·
GSK,
·
Boehringer,
·
Amgen,
·
Boehringer,
·
Merck,
·
Amgen, and
·
Eli Lilly.
Drivers and Constraints Impacting the Market
The global ticagrelor
market is estimated to register a healthy CAGR due to several driving factors.
With increasing patient population suffering from heart problems, the market is
estimated to foster during the assessment period.Increasing product developmentby
the companies, funding for research and development activities by the major market
players, and improving market access scenarios are further estimated to propel
the market. Moreover, owing to the presence of several well-established
players, the ticagrelor market is estimated to flourish in the coming years.
On the flip
side, side effects of ticagrelor such as chest pain, irregular heartbeat, shortness
of breath, nose bleeding, and spots under the skin are some of the major
concerns considered to impede the market growth during the estimated period.
Global Ticagrelor Market: Segmental Analysis
The global
ticagrelor market has been segmented on the basis of end-users and region.
By mode of
end-users, the global ticagrelor market has been segmented into hospitals,
clinics, and medical institutions. Among these, the hospital segment is
considered to experience a significant growth rate during the assessment period
owing to the well-developed infrastructure and latest devices offered by the
hospitals. Moreover, rising incidences of heart attacks are propelling the
segment growth.
Regional Insights
Geographically,
the ticagrelor
market insights span across regions namely, Europe, Americas,Asia Pacific,
and the Middle East & Africa.
Among all the
regions, America occupies the largest market share of approx. more than 40%
owing to the extensive use of the drug by the patients who are discharged from
hospitals in this region. Moreover, presence of major manufactures in this
region is further contributing to the market growth.
Europe is
estimated to be the second largest market and is anticipated to maintain its
dominance during the appraisal period owing to the increasing awareness of
ticagrelor in this region. Moreover, well-developed hospital infrastructure has
further promoted the market growth.
The Asia Pacific
region is considered to expand at the fastest growth rate owing to the increased
number of cardiovascular patients in this region. Economies such as China and
India are predicted to be the fastest growing regions. Moreover, major key
players are expanding their presence in this region which is further
contributing to the market growth. For instance, Sun Pharmaceutical Industries
Ltd.and AstraZeneca Pharma India Limited had announced that they had entered
entered into a distribution services agreement in India for Axcer, which is a
new brand of ticagrelor.
On the other
hand, the Middle East & Africa is presumed to occupy the least market share
owing to poor medical facilities, lack of awareness, and limited market
scenario activities.
Market Research Future (MRFR), enable customers to unravel the
complexity of various industries through Cooked Research Report (CRR),
Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed
Research (CFR), and Market Research & Consulting Services.
Contact us:
Market Research Future (part of Wantstats Research and Media Private
Limited),
99 Hudson Street,5Th Floor, New York,
New York 10013
United States of America
